AIM IMMUNOTECH INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-53.3% -$24K
$21K
Cost of Revenue
—
R&D↓-36.1% -$601K
$1M
D&A↑+0.0% +$0
$9K
Operating Income↑+45.5% +$2M
$-2M
EBITDA↑+0.0% +$0
$9K
Interest Expense↑+196.2% +$259K
$391K
Net Income↑+11.2% +$416K
$-3M
Operating Margin↑+3414.2pts
-9411.5%
Net Margin↓-2059.3pts
-12630.8%
DTA Valuation Allowance↑+11.5% +$4M
$38M
Tax Credit Carryforwards
—
NOL Carryforwards
—
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+0.0pts
7.6%
ETR Foreign Differential (pp)
-0.0%
Operating Lease Cost↓-9.0% -$7K
$71K
Revenue YoY Variation↓-22.6pts
-53.3%
Income YoY Variation↑+0.5pts
45.5%
Revenue QoQ Variation↓-47.8pts
-19.2%
Income QoQ Variation↑+29.0pts
7.5%